Compare Avalanche Treasury Corporation Class A Common Stock (AVAT) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avalanche Treasury Corporation Class A Common Stock vs BioNano Genomics Inc — how do they compare? Avalanche Treasury Corporation Class A Common Stock trades at $0.52 (market cap $21.65M), while BioNano Genomics Inc trades at $1.15 (market cap $13.20M). The key difference: Avalanche Treasury Corporation Class A Common Stock is the larger of the two by market cap. Which is the better fit depends on your goals.
| AVAT | BNGO | |
|---|---|---|
Market Cap | $21.65M | $13.20M |
Sector | Financials | Health |
52-Week High | $10.75 | $4.92 |
52-Week Low | $0.51 | $1.09 |
Enterprise Value | $21.65M | $15.81M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVAT stock trades at $0.506, down 6.3% today, with a bearish technical signal from moving averages. The company shows mixed fundamentals with a low P/E of 12 and P/B of 0.4, but negative cash flow from operations at -$930,710 in 2025. Recent Nasdaq listing news highlights its role as an operating company and digital asset treasury focused on capital allocation across the Avalanche economy.
The outlook remains cautious due to negative operational cash flow and bearish technical indicators. Investment opportunity lies in the discounted valuation multiples, while risks include sustained cash burn and competitive pressures in treasury management services. Market sentiment is neutral with recent media coverage of the Nasdaq debut.
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Avalanche Treasury Corporation Class A Common Stock
Avalanche Treasury Corp operates as a digital asset treasury company focused on holding and managing digital asset investments. The company was founded on September 22, 2025, and is headquartered in New York, NY.
Read more on AVAT →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
